Dacula, Hamima .

HRN: 27-98-49  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/22/2025
AMPICILLIN 250MG (VIAL)
10/22/2025
10/29/2025
IV
160mg
Q 12
T/C Neonatal Pneumonia
Waiting Final Action 
10/22/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/22/2025
10/29/2025
IV
48mg
Q 24
T/C Neonatal Pneumonia
Waiting Final Action 
10/28/2025
CEFTAZIDIME 1GM (VIAL)
10/28/2025
11/04/2025
IV
160mg
Q8
Neonatal Penumonia T/c Sepsis
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: